Physician profile
Allen Jay Denison
NPI 1205876190
$2,702.03
in general payments reported to CMS, 2019-2025
13 companies · $488 in 2025
The $488 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $399 · 2021: $265 · 2022: $451 · 2023: $438 · 2024: $298 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $772.64 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $437.57 | 2020-2025 | Rocklatan, Tryptyr, Precision 1 |
| Coopervision INC. | $334.94 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $329.81 | 2022-2025 | Xiidra, Miebo, Infuse |
| Glaukos Corporation | $275.59 | 2023-2025 | Idosetr, Iaccess Precision Blade |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $162.07 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $128.07 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $100.00 | 2020 | |
| Biotissue Holdings INC. | $57.10 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $36.84 | 2023 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Oyster Point Pharma, INC. | $32.22 | 2024 | Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abbvie INC. | $15.78 | 2023 | Durysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Denison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.